Mapping a Path to
Breakthrough Therapies
Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer
Discover the science![Snipe kartos chain 20210725](https://kartosthera.com/assets/images/home/home_MDM2-nav-p53@2x.png)
MDM2
KRT-232
p53
The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients across selected solid tumors and hematological malignancies
Navtemadlin (KRT-232)
A novel, potent, and selective oral MDM2 inhibitor
Active Clinical StudiesKRT-232
MDM2
![Snipe navtemadlin krt232 mdm2 desktop](https://kartosthera.com/assets/images/home/home_Nav-MDM2@2x_2022-11-21-091344.png)